Benefits
Vegan and vegetarian source of preformed EPA and DHA
The fundamental positioning. Fish-derived omega-3 is incompatible with strict vegan and many vegetarian diets, and plant-derived ALA from flax, chia, walnut, and hemp converts to long-chain omega-3 at very low rates in humans — typically less than 5% to EPA and less than 0.5% to DHA, with men converting even less efficiently than women. Algal oil bypasses this conversion bottleneck entirely. For long-term vegans, algal DHA (along with B12 and often vitamin D) is generally treated as an essential rather than optional supplement.
Bioavailability comparable to fish oil
A 2025 randomized head-to-head trial in 74 adults over 14 weeks (Int J Mol Sci) compared plasma phospholipid DHA and EPA levels from microalgal oil vs. fish oil. Microalgal oil was statistically non-inferior, with combined geometric mean ratios of 112%. An earlier crossover RCT (Vega-López 2022) at 250 mg DHA/day in 116 omnivores, vegetarians, and vegans showed marked serum DHA increases independent of baseline diet or sex. The algal triglyceride form (≥90% TG) is structurally similar to fish-derived natural triglyceride fish oil and avoids the lower bioavailability of ethyl ester forms.
Pregnancy DHA — DOMInO trial evidence
DOMInO (JAMA) randomized 2,399 Australian pregnant women to 800 mg DHA/day from <21 weeks gestation or vegetable oil placebo. Primary outcome (maternal depression scores at 6 weeks and 6 months postpartum) did not differ significantly. However, DHA supplementation reduced preterm birth (<34 weeks) and increased gestational age. Subsequent follow-up confirmed the preterm-birth reduction is the most reliable benefit, particularly in women with low baseline DHA status. Cognitive benefits in well-nourished, full-term infants have been less consistent than originally hypothesized.
Infant formula fortification — life'sDHA
Algal DHA has been the standard source for infant formula DHA fortification globally since the early 2000s. DSM (formerly Martek)'s life'sDHA® is the dominant commercial source, present in essentially all major infant formulas in the US and EU. Breastfed infants depend on maternal DHA status; formula-fed infants need fortified formula because cow milk and standard vegetable oils don't supply DHA. This is the largest single use of algal DHA by volume globally.
Cognitive support in older adults
Yurko-Mauro et al. 2010 (MIDAS trial) randomized 485 healthy adults aged ≥55 with age-related cognitive decline to 900 mg DHA/day from algal oil or placebo for 24 weeks. DHA improved learning and episodic memory scores, with a doubling of plasma DHA in the supplemented group. Aligns with the broader DHA evidence in cognitive aging — most consistent in adults with low baseline DHA intake or early cognitive complaints rather than in young, well-nourished adults.
DHA-only formulations vs. EPA+DHA combinations
Most algal oils are DHA-predominant. EPA and DHA have functionally distinct effects: EPA dominates the cardiovascular and depression evidence (REDUCE-IT, MDD meta-analyses), while DHA is more important for fetal/infant brain development, retinal function, and possibly cognitive aging. For anti-inflammatory, mood, or cardiovascular indications, choose an algal oil that provides EPA in addition to DHA — DHA-only products may be insufficient. Algal EPA strains are now commercially available; this gap is closing.
Sustainability and contamination profile
Algal oil is produced in controlled fermentation tanks — no wild fish caught, no marine contamination, no impact on ocean stocks. Mercury, PCBs, and dioxins that accumulate in marine food chains are absent. Particularly relevant during pregnancy and for children, where mercury exposure is a significant concern with some fish oil products. Note that fish accumulate DHA from eating algae — so algal oil is in fact the original biosynthetic source of marine DHA, not a substitute.
Mechanism of action
Biochemically identical to fish-derived DHA
DHA molecules from algae and fish are identical — same C22:6n-3 fatty acid structure, same metabolic fate, same cellular incorporation. Once consumed and absorbed, the body cannot distinguish source. All DHA-mediated mechanisms (membrane phospholipid composition, eicosanoid modulation, specialized pro-resolving mediator synthesis) operate identically.
Brain and retinal phospholipid incorporation
DHA is the most abundant long-chain polyunsaturated fatty acid in brain gray matter and retinal photoreceptor outer segments. It comprises roughly 15-20% of frontal cortex fatty acids and over 50% of retinal photoreceptor phospholipids. This concentration drives the recommendations for fetal/infant supplementation (rapid brain DHA accretion in the third trimester and first two years) and the cognitive-aging hypothesis.
Triglyceride form for absorption
Schizochytrium-derived DHA is naturally produced in triglyceride form (≥90% TG), the form that the small intestine processes most efficiently via pancreatic lipase. Avoids the lower bioavailability seen with fish oil ethyl ester preparations, which require additional enzymatic conversion before absorption.
Eicosanoid modulation (DHA-driven, weaker than EPA)
DHA partially displaces arachidonic acid in cell membranes, shifting eicosanoid production toward less inflammatory series-3 prostaglandins and toward DHA-derived specialized pro-resolving mediators (D-series resolvins, protectins, maresins). However, EPA is the more potent eicosanoid modulator — DHA-only algal oils are weaker for inflammatory and cardiovascular indications than EPA-containing formulations.
Closed-system production
Schizochytrium is grown heterotrophically in closed stainless-steel fermenters using sugar substrates rather than in open ponds requiring sunlight. Tightly controlled growth conditions, harvested biomass extracted and refined to food-grade oil. Production is independent of weather, fishery quotas, or ocean conditions, supporting consistent quality and supply.
Clinical trials
Multi-center double-blind clinical trial in 2,399 Australian pregnant women under 21 weeks gestation. Randomized to 800 mg/day DHA from algal-source fish oil capsules vs.
pregnant women
Multi-center double-blind clinical trial in 2,399 Australian pregnant women under 21 weeks gestation. Randomized to 800 mg/day DHA from algal-source fish oil capsules vs. vegetable oil placebo from study entry to birth. Primary outcome (maternal depression at 6 weeks/6 months postpartum) did not differ significantly. Reduction in preterm birth (<34 weeks) and increased gestational age were observed. Subsequent KUDOS and ORIP (NEJM 2018) trials replicated the preterm-birth reduction, especially in low-DHA-status women.
Clinical trial in 485 healthy adults aged ≥55 with age-related cognitive decline.
485 healthy adults
Clinical trial in 485 healthy adults aged ≥55 with age-related cognitive decline. 900 mg/day algal DHA or placebo for 24 weeks. Improvements in learning and episodic memory. Plasma DHA approximately doubled in the supplemented group, confirming bioavailability and adherence.
Randomized double-blind placebo-controlled trial in 74 adults with low baseline DHA intake.
74 adults with low baseline DHA intake
Randomized double-blind placebo-controlled trial in 74 adults with low baseline DHA intake. 14 weeks of microalgal oil, fish oil, or placebo. Primary endpoint: plasma phospholipid DHA + EPA. Microalgal oil was statistically non-inferior to fish oil with combined geometric mean ratio of 112%. Established direct evidence that algal omega-3 delivers comparable systemic exposure to fish oil at matched doses.
Randomized double-blind placebo-controlled crossover in 116 omnivores, lacto-ovo vegetarians, and vegans. 250 mg/day algal DHA from Schizochytrium for 5 weeks per arm.
Clinical population described in trial publication.
Randomized double-blind placebo-controlled crossover in 116 omnivores, lacto-ovo vegetarians, and vegans. 250 mg/day algal DHA from Schizochytrium for 5 weeks per arm. Marked increase in serum DHA independent of baseline diet or sex. Reduced intermediate metabolites DPA-n3 and ADA-n6, with EPA preserved. Confirms that low-dose algal DHA is sufficient to raise circulating DHA in plant-based diet patterns.